NEW OPPORTUNITIES IN TREATMENT OF CHRONIC HEART FAILURE WITH NORMAL EJECTION FRACTION

NEW OPPORTUNITIES IN TREATMENT OF CHRONIC HEART FAILURE WITH NORMAL EJECTION FRACTION

Aim. To evaluate aim worthiness and efficacy of the application of angiotensin type II receptor blockers (ARB) and calcium channel antagonists (CCA) in patients with early stages of chronic heart failure with normal ejection fraction (CHF-NEF) developed on the background of arterial hypertension and...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. G. Dushina, R. A. Libis
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2015-08-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	chronic heart failure with normal ejection fraction calcium channel antagonists angiotensin ii receptor blockers
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/247
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Features of chronic heart failure depending on the left ventricular ejection fraction
by: A. G. Dushina, et al.
Published: (2019-03-01)

Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review
by: A. A. Kuzmenko, et al.
Published: (2022-10-01)

EFFECT OF ANGIOTENSIN-II RECEPTOR ANTAGONIST LOSARTAN AND ITS COMBINATION WITH DIURETICS ON MYOCARDIAL MORPHO-FUNCTIONAL CONDITIONS IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY
by: S. N. Tolpygina, et al.
Published: (2016-01-01)

Comparison of mouse models of heart failure with reduced ejection fraction
by: Nabil V. Sayour, et al.
Published: (2025-02-01)

Heart Failure with Preserved Ejection Fraction in the Indian Context
by: Rajeev Gupta, et al.
Published: (2025-04-01)

Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?
by: V. D. Zakiev, et al.
Published: (2023-12-01)

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
by: A. S. Ryazanov, et al.
Published: (2023-01-01)

Impact of antihypertensive drug classes on cardiovascular outcomes: insights from the STEP study
by: Xinyi Peng, et al.
Published: (2025-07-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

THE ROLE OF DIET AND PHYSICAL ACTIVITY IN THERAPY OF CARDIOVASCULAR PATIENTS WITH NORMAL EJECTION FRACTION
by: O. M. Drapkina, et al.
Published: (2017-04-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

Heart rate-lowering antianginal medications: what determines their choice?
by: Yu. M. Lopatin
Published: (1970-01-01)

Characterizing Heart Failure Across the Spectrum of the Preserved Ejection Fraction: Does Heart Failure With Supranormal Ejection Fraction Exist? Data From the Swedish Heart Failure Registry
by: Laura Landucci, et al.
Published: (2025-03-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

Impact of Doxorubicin on Cardiac Function in Dogs: Ejection Fraction Changes and Heart Failure Risk
by: Gustavo Cavinato Herrera, et al.
Published: (2025-09-01)

Angiotensin II type 1 receptor antagonists and their combinations in the treatment of hypertension
by: J.A. Ker
Published: (2012-06-01)

TREATMENT OF HYPERTENSION IN PREGNANCY: GUIDELINES AND CLINICAL EXPERIENCE
by: O. V. Gaisenok, et al.
Published: (2015-09-01)

Clinical management of heart failure with improved ejection fraction: treatment and maintenance
by: XU Tianyun, et al.
Published: (2025-04-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Features of phenotyping patients with heart failure with preserved ejection fraction
by: E. K. Serezhina, et al.
Published: (2023-09-01)

In-Hospital Mortality and Costs of Added Morbidity in Heart Failure Patients at a University Hospital: A Retrospective Cross-Sectional Study
by: Lourdes Raya Ortega, et al.
Published: (2025-05-01)

An update of medical care in Marfan syndrome
by: Hsin-Hui Chiu
Published: (2022-01-01)

Influence of aldosterone antagonists on markers of electrophysiological instability in patients with heart failure with mid-range ejection fraction after ST-segment elevation acute coronary syndrome in the short- and long-term periods
by: L. V. Shekhovtsova, et al.
Published: (2020-11-01)

Left atrioventricular coupling index measured by echocardiography in heart failure with preserved ejection fraction
by: Hai Nguyen Ngoc Dang, et al.
Published: (2025-07-01)

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes
by: D. A. Lebedev, et al.
Published: (2020-11-01)

Markers of heart failure with preserved ejection fraction in patients with unexplained dyspnea
by: A. A. Ivanova, et al.
Published: (2023-11-01)

VESSEL WALL STIFFNESS IN ARTERIAL HYPERTENSION AND OPPORTUNITIES FOR ITS MODULATION
by: L. L. Kirichenko, et al.
Published: (2016-12-01)

Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives
by: O. V. Tsygankova, et al.
Published: (2021-05-01)

Clinical characteristics and outcomes in Asian patients with heart failure with mildly reduced ejection fraction
by: Julian Cheong Kiat Tay, et al.
Published: (2024-07-01)

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)

BLOOD PRESSURE-LOWERING EFFICACY OF OLMESARTAN RELATIVE TO OTHER ANGIOTENSIN II RECEPTOR ANTAGONISTS: AN OVERVIEW OF RANDOMIZED CONTROLLED STUDIES
by: Faiez Zannad, et al.
Published: (2010-08-01)

First-phase ejection fraction is associated with myocardial fibrosis in the pressure overloaded heart
by: Shukun He, et al.
Published: (2025-07-01)

Preoperative continuation vs. discontinuation of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on early cognitive function in elderly patients undergoing noncardiac surgery: a randomized controlled trial
by: Xiaohan Wang, et al.
Published: (2025-03-01)

The Effect of ACE Inhibitors/ARBs Withdrawal on the Risk of Postoperative Complications in Abdominal Surgery
by: N. V. Trembach, et al.
Published: (2023-10-01)

NEW POSSIBILITIES OF STATIN THERAPY IN ARTERIAL HYPERTENSION
by: E. M. Khurs, et al.
Published: (2016-01-01)

Angioprotection role in arterial hypertension treatment: focus on olmesartan
by: D. V. Nebieridze, et al.
Published: (2012-10-01)

Temporal left ventricular ejection fraction variations and outcomes in wide population of cardiovascular patients with and without heart failure
by: Radosław Szczerba, et al.
Published: (2025-03-01)

Characteristics of patients with chronic heart failure with mildly reduced ejection fraction: clinical and demographic aspect
by: M. T. Duishenalieva, et al.
Published: (2025-05-01)